Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of ivonescimab versus pembrolizumab as first-line treatment for metastatic NSCLC with high PD-L1 expression
NL-OMON61809Phase 3Not yet recruiting
- Sponsor
- Summit Therapeutics
- Start
- May 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of ivonescimab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Summit Therapeutics. Primary endpoints: Overall survival and Progression-free survival. Planned start May 2025; status: not yet recruiting.
02
Drugs
ivonescimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON61809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61809.